Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
© 2022. The Author(s)..
BACKGROUND: Allopurinol (ALP), a xanthine oxidase inhibitor, is a first line drug for the treatment of gout and hyperuricemia. Being the member of BCS class II drugs, ALP has solubility problem, which affects its bioavailability. Also, ALP has shorter half-life and showed GI related problems. In present study, ALP was encapsulated in nanostructured lipid carriers (NLCs) to ensure enhanced bioavailability, improved efficacy and safety in vivo.
METHODOLOGY: ALP-loaded NLCs were fabricated by micro-emulsion technique. The prepared NLCs were optimized via design expert in term of particle size, zeta potential and entrapment efficiency. FTIR, PXRD and TEM analysis were carried out to check chemical interaction, polymorphic form and surface morphology of the optimized formulation. ALP-loaded NLCs were then loaded into HPMC based poloxamer-407 gel and were characterized. In vitro and ex vivo analysis were carried out via dialysis membrane method and franz diffusion cell, respectively. Uric acid was used for induction of gout and the anti-gout activity of ALP-loaded NLCs gel was performed and compared with ALP suspension.
RESULTS: The optimized formulation had particles in nano-range (238.13 nm) with suitable zeta potential (-31.5 mV), poly-dispersity index (0.115) and entrapment of 87.24%. FTIR results confirmed absence of chemical interaction among formulation ingredients. XRD indicated amorphous nature of ALP-loaded NLCs, whereas TEM analysis confirmed spherical morphology of nanoparticles. The optimized formulation was successfully loaded in to gel and characterized accordingly. The in vitro release and drug release kinetics models showed sustained release of the drug from ALP-loaded NLCs gel. Furthermore, about 28 fold enhanced permeation was observed from ALP-loaded NLCs gel as compared to conventional gel. Skin irritation study disclosed safety of ALP-loaded NLCs gel for transdermal application. Furthermore, ALP-loaded NLCs gel showed significantly enhanced anti-gout activity in Sprague-Dawley rats after transdermal administration as compared to oral ALP suspension.
CONCLUSION: ALP-loaded NLCs gel after transdermal administration sustained the drug release, avoid gastrointestinal side effects and enhance the anti-gout performance of ALP. It can be concluded, that NLCs have the potential to deliver drugs via transdermal route as indicated in case of allopurinol.
Errataetall: |
RetractionIn: BMC Pharmacol Toxicol. 2023 Jul 12;24(1):40. - PMID 37438845 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC pharmacology & toxicology - 23(2022), 1 vom: 28. Nov., Seite 86 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ali, Zakir [VerfasserIn] |
---|
Links: |
---|
Themen: |
63CZ7GJN5I |
---|
Anmerkungen: |
Date Completed 30.11.2022 Date Revised 12.07.2023 published: Electronic RetractionIn: BMC Pharmacol Toxicol. 2023 Jul 12;24(1):40. - PMID 37438845 Citation Status MEDLINE |
---|
doi: |
10.1186/s40360-022-00625-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM349566763 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM349566763 | ||
003 | DE-627 | ||
005 | 20231226042935.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s40360-022-00625-y |2 doi | |
028 | 5 | 2 | |a pubmed24n1165.xml |
035 | |a (DE-627)NLM349566763 | ||
035 | |a (NLM)36443818 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ali, Zakir |e verfasserin |4 aut | |
245 | 1 | 0 | |a Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.11.2022 | ||
500 | |a Date Revised 12.07.2023 | ||
500 | |a published: Electronic | ||
500 | |a RetractionIn: BMC Pharmacol Toxicol. 2023 Jul 12;24(1):40. - PMID 37438845 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a BACKGROUND: Allopurinol (ALP), a xanthine oxidase inhibitor, is a first line drug for the treatment of gout and hyperuricemia. Being the member of BCS class II drugs, ALP has solubility problem, which affects its bioavailability. Also, ALP has shorter half-life and showed GI related problems. In present study, ALP was encapsulated in nanostructured lipid carriers (NLCs) to ensure enhanced bioavailability, improved efficacy and safety in vivo | ||
520 | |a METHODOLOGY: ALP-loaded NLCs were fabricated by micro-emulsion technique. The prepared NLCs were optimized via design expert in term of particle size, zeta potential and entrapment efficiency. FTIR, PXRD and TEM analysis were carried out to check chemical interaction, polymorphic form and surface morphology of the optimized formulation. ALP-loaded NLCs were then loaded into HPMC based poloxamer-407 gel and were characterized. In vitro and ex vivo analysis were carried out via dialysis membrane method and franz diffusion cell, respectively. Uric acid was used for induction of gout and the anti-gout activity of ALP-loaded NLCs gel was performed and compared with ALP suspension | ||
520 | |a RESULTS: The optimized formulation had particles in nano-range (238.13 nm) with suitable zeta potential (-31.5 mV), poly-dispersity index (0.115) and entrapment of 87.24%. FTIR results confirmed absence of chemical interaction among formulation ingredients. XRD indicated amorphous nature of ALP-loaded NLCs, whereas TEM analysis confirmed spherical morphology of nanoparticles. The optimized formulation was successfully loaded in to gel and characterized accordingly. The in vitro release and drug release kinetics models showed sustained release of the drug from ALP-loaded NLCs gel. Furthermore, about 28 fold enhanced permeation was observed from ALP-loaded NLCs gel as compared to conventional gel. Skin irritation study disclosed safety of ALP-loaded NLCs gel for transdermal application. Furthermore, ALP-loaded NLCs gel showed significantly enhanced anti-gout activity in Sprague-Dawley rats after transdermal administration as compared to oral ALP suspension | ||
520 | |a CONCLUSION: ALP-loaded NLCs gel after transdermal administration sustained the drug release, avoid gastrointestinal side effects and enhance the anti-gout performance of ALP. It can be concluded, that NLCs have the potential to deliver drugs via transdermal route as indicated in case of allopurinol | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Retracted Publication | |
650 | 4 | |a Allopurinol | |
650 | 4 | |a Anti-gout study | |
650 | 4 | |a Nanostructured lipid carriers | |
650 | 4 | |a Transdermal | |
650 | 7 | |a Allopurinol |2 NLM | |
650 | 7 | |a 63CZ7GJN5I |2 NLM | |
650 | 7 | |a Lipids |2 NLM | |
700 | 1 | |a Din, Fakhar Ud |e verfasserin |4 aut | |
700 | 1 | |a Zahid, Fatima |e verfasserin |4 aut | |
700 | 1 | |a Sohail, Saba |e verfasserin |4 aut | |
700 | 1 | |a Imran, Basalat |e verfasserin |4 aut | |
700 | 1 | |a Khan, Salman |e verfasserin |4 aut | |
700 | 1 | |a Malik, Maimoona |e verfasserin |4 aut | |
700 | 1 | |a Zeb, Alam |e verfasserin |4 aut | |
700 | 1 | |a Khan, Gul Majid |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC pharmacology & toxicology |d 2012 |g 23(2022), 1 vom: 28. Nov., Seite 86 |w (DE-627)NLM220735107 |x 2050-6511 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2022 |g number:1 |g day:28 |g month:11 |g pages:86 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40360-022-00625-y |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2022 |e 1 |b 28 |c 11 |h 86 |